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Formation and Persistence of Arylamine
DNA Adducts In Vivo
by Frederick A. Beland* and Fred F. Kadlubar*
Aromatic amines are urinary bladder carcinogens in man and induce tumors at a number of sites in
experimental animals including the liver, mammary gland, intestine, and bladder. In this review, the
particular pathways involved in the metabolic activation ofaromatic amines are considered as well as the
specific DNAadducts formed intarget and nontargettissue. Particular emphasis is placedon the following
compounds: 1-naphthylamine, 2-naphthylamine, 4-aminobiphenyl, 4-acetylaminobiphenyl, 4-acetyl-
amino4'-fluorobiphenyl, 3,2'-dimethyl-4-aminobiphenyl, 2-acetylaminofluorene, benzidine, N-methyl-4-
aminoazobenzene, 4-aminoazobenzene, and 2-acetylaminophenanthrene.
Introduction
Aromatic amines and amides were originally associ-
ated with the induction of bladder tumors in man and
have subsequently been found to be carcinogenic at a
number of sites in a variety of experimental animals
(1,2). The initial step inthe metabolic activation ofthese
compounds usually involves an N-oxidation (Fig. 1),
which can be catalyzed by cytochrome P-450, the flavin-
containing monooxygenase (FMO), orperoxidases, such
as prostaglandin H synthase (PHS). Primary aryl-
amines are N-oxidized to N-hydroxy arylamines that
can undergo an acid-catalyzed reaction with DNA or
can be further metabolized to a reactive electrophile
through acetyl coenzyme A (AcCoA)-dependent 0-ace-
tylation, ATP-dependent 0-aminoacylation, or 3'-phos-
phoadenosine 5'-phosphosulfate (PAPS)-dependent 0-
sulfonylation. The N-oxidation ofsecondary arylamines
results in N-hydroxy metabolites that do not react di-
rectly with DNA but are further converted into elec-
trophilic derivatives by 0-sulfonylation.
Aromatic amides are N-oxidized only by the cyto-
chrome P450 monooxygenases, and since the N-hy-
droxy arylamides (arylhydroxamic acids) that are fonned
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FIGURE 1. Metabolic pathways leading to DNA adducts from arylamines and arylamides.
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are not reactive, further metabolic activation is re-
quired. This canbe accomplished by atleastthree path-
ways: O-sulfonylation, deacetylation to a N-hydroxy
arylamine, or intramolecular N,O-acyltransfer to a N-
acetoxy arylamine. In this review, we consider how
these various metabolic pathways lead to the specific
arylamine and arylamide DNA adducts that have been
detected in vivo. We also discuss the relationship be-
tween the persistence of specific adducts and tumor
induction.
1-Naphthylamine
Although 1-naphthylamine (1-NA)hasnotbeen found
to be carcinogenic inanybioassay (1,3,4), itsN-oxidized
derivative, N-hydroxy-1-NA, is strongly carcinogenic
at sites ofapplication (5-7). The in vitro reaction ofN-
hydroxy-1-NA with DNA yields at least three adducts
(Fig. 2): N-(deoxyguanosin-O6-yl)-1-NA, 2-(deoxy-
guanosin-O6-yl)-1-NA, and a decomposition product of
the latter adduct (8). N-(Guan-8-yl)-1-NA has also been
isolated after acidic hydrolyis of N-hydroxy-1-NA-
treated DNA (9) but has not been detected after en-
zymatic hydrolysis (Kadlubar, unpublished observa-
tion). As with other primary N-hydroxy arylamines,
DNA adduct formation with N-hydroxy-1-NA is acid-
catalyzed and is 20-fold greater at pH 5 as compared to
pH 7.
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FIGURE 2. DNA adducts derived from 1-naphthylamine.
The DNA adducts formed at the subcutaneous injec-
tion site ofrats administered N-hydroxy-l-NA have re-
cently been examined (7). N-(Deoxyguanosin-O6-yl)-1-
NA was the major adduct detected 1 day after treat-
ment and the total binding decreased by only 30% dur-
ing the next 6 days. N-Hydroxy-l-NA bound to the
DNA20-foldbetterthantheisomericN-hydroxy-2-NA,
which was consistent with the relative carcinogenicity
of the two compounds. Furthermore, alternating the
administration ofbothN-hydroxyarylaminesdecreased
both the incidence ofN-hydroxy-l-NA-induced tumors
and the persistence of the adducts resulting from this
compound.
Dogs have been used extensively as a model for
arylamine carcinogenesis in man. Therefore, as part of
a study relating the extent of adduct formation to car-
cinogenic potency, the binding of 1-NA to hepatic and
urothelial DNA of dogs was assessed (10,11). Adduct
fonnation from 1-NA was not detected in urothelial DNA
and only very low levels were found in hepatic DNA.
The failure to detect significant binding could indicate
very efficient DNA repair processes or, alternatively,
mayindicate that 1-NAcannotbe activated invivo. The
latterpossibilityappearsmorelikelybecauseinarecent
study (12), cytochromes P-450 and FMO from anumber
of species were unable to catalyze the oxidation of 1-
NA to N-hydroxy-1-NA.
2-Naphthylamine
In contrast to 1-NA, its isomer 2-NA is carcinogenic
in anumber ofspecies includingrats, dogs, and humans
(1). When the N-oxidized derivative, N-hydroxy-2-NA,
was reacted in vitro at pH 5 with DNA, three adducts
were detected (Fig. 3): an imidazole ring-opened deriv-
ative of N-(deoxyguanosin-8-yl)-2-NA(50%), 1-(deoxy-
guanosin-N2-yl)-2-NA(30%)), and 1-(deoxyadenosin-N6-
yl)-2-NA (15%) (13). Although 2-NAis carcinogenic and
1-NA is not, it should be noted that the N-hydroxy
derivative of2-NAdoes notbind to DNAinvitro nearly
as well as does N-hydroxy-1-NA (14). This difference
in binding also occurs in vivo because, as mentioned
above, N-hydroxy-2-NA bound to injection site DNA
in rats to a much lower extent than was found with N-
hydroxy-1-NA (7). This reduced binding was probably
responsible for the small tumor yield being recorded
with N-hydroxy-2-NA.
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FIGURE 3. DNA adducts derived from 2-naphthylamine.
The DNA adduct derived from 2-NA in target (uro-
thelium) and nontarget (liver) tissues ofdogs have also
been reported (10,11). Two days following the oral
administration of 2-NA, the same three adducts that
were found in vitro from N-hydroxy-2-NA were de-
tected in both tissues with 4-fold higher binding levels
being observed in the urothelial DNA. The major prod-
uct in both tissues was the ring-opened derivative ofN-
(deoxyguanosin-8-yl)-2-NA, followed by lower levels of
1-(deoxyadenosin-N;-yl)-2-NA and 1-(deoxyguanosin-N2-
yl)-2-NA. Although there is not an exact correspond-
ence between the ratios ofadducts found invivo and in
vitro, the commonality of adducts suggests that N-hy-
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droxy-2-NA could be the ultimate carcinogenic species
invivo. This view is strengthened byapharmacokinetic
model which correctly predicts bladder tumor suscep-
tibility in different species as a function of urine pH,
voiding interval and resorption (15).
Whentheextentofbindingwasmeasured 7daysafter
2-NA administration, the N2-deoxyguanosine adduct
appeared to persist in the dog liver, while both this
adduct and the C8-deoxyguanosine adduct persisted in
the bladder(10,11). The differential loss of adducts in-
dicates that active repair processes are present in both
tissues, and the relative persistence of the C8-deoxy-
guanosine adduct in target but not in the nontarget
tissue suggests that this adduct may be a critical lesion
for the initiation of urinary bladder tumors.
Peroxidative enzymes, such as PHS, have been shown
to catalyze both the N- and ring-oxidation of2-NA (16).
When DNA was included in these in vitro incubations,
six adducts were detected (17), three arising from N-
hydroxy-2-NA, while the remaining three appeared to
be formed from 2-imino-1-naphthoquinone, the oxida-
tive product of2-amino-1-naphthol (Fig. 4). Since PHS
activity has been demonstrated in the dog bladder (18),
additional experiments were conducted to determine if
2-amino-1-naphthol-derived adducts could be detected
in vivo (17). Two days following the administration of
2-NA, adducts that accounted for about 20% ofthe total
binding and that were indicative of2-imino-1-naphtho-
quinone formation were identified in urothelial but not
liver DNA. Thus, it appears that PHS may have a sig-
nificant role in arylamine bladder carcinogenesis.
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FIGURE 4. Metabolic activation of 2-naphthylamine by prostaglan-
din H synthase.
4-Aminobiphenyl and
4-Acetylaminobiphenyl
The arylamide, 4-acetylaminobiphenyl (AABP), dif-
fers from a number of aromatic amides in that its pri-
mary target in rats is the mammary gland as opposed
to the liver (19). Although the adducts in the mammary
gland have not been characterized, Kriek (20) has com-
pared the binding of AABP to hepatic DNA with that
of the strong hepatocarcinogen 2-acetylaminofluorene
(AAF) in order to determine why AABP is such a poor
inducer of liver tumors. Following administration of a
single dose of the presumed proximate carcinogen, N-
hydroxy-AABP, the total binding to hepatic DNA was
about 25% of that found with the hydroxamic acid of
AAF. When the individual adducts were examined, ap-
proximately 20% retained their acetyl groups and thus
presumably arose from a sulfotransferase-catalyzed in-
termediate, while the remaining 80% were nonacety-
lated and may have resulted from deacetylation, N,O-
acetyltransfer (21), or deacetylation followed by acetyl
coenzyme A-dependentO-acetylation(22). Althoughthe
nonacetylated adducts were not characterized, the acet-
ylated adducts were subsequently identified (23) as 3-
(deoxyguanosin-N2-yl)-AABP andN-(deoxyguanosin-8-
yl)-AABP (Fig. 5).
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FIGURE 5. DNA adducts derived from 4-acetylaminobiphenyl and
4-aminobiphenyl.
Recently Gupta and Dighe (24) have used a 3P-post-
labelingtechnique to examine the types and persistence
of adducts following the IP administration of several
arylhydroxamic acids to rats. Maximum binding of N-
hydroxy-AABP to hepatic DNA was observed 30 min
after treatment but the value was only about 10% of
the maximum value found with a similar dose of N-
hydroxy-AAF. Initially, the binding rapidly decreased,
by 50% in 4 hr and 75% in 24 hr, and then more slowly,
resultinginapproximately 10%oftheadductspersisting
after 29 days. The major adduct (ca. 70%) was a non-
acetylated product which coeluted with a N-(deoxy-
guanosin-8-yl)-4-aminobiphenyl (ABP) standard (Fig.
5), while an additional nonacetylated adduct accounted
for 7% of the initial binding. Two acetylated adducts
were also detected; N-(deoxyguanosin-8-yl)-AABP was
the major acetylated product (13%), while an adduct
tentatively identified as 3-(deoxyguanosin-N2-yl)-AABP
was found in smaller amounts. After 29 days, the only
adducts that were detected were the two nonacetylated
ones as well as 3-(deoxyguanosin-N2-yl)-AABP.
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Among the aromatic amine carcinogens, ABP is the
most potent bladder carcinogen in dogs (25). Since dogs
are deficient in N-acetylases (26,27), N-hydroxy aryl-
amines have been proposed to be the ultimate carcin-
ogenic form in this species. WhenN-hydroxy-ABP was
reacted with calf thymus DNA at pH 5, three adducts
resulted (Fig. 5): N-(deoxyguanosin-8-yl)-ABP (80%),
N-(deoxyadenosin-8-yl)-ABP (15%), and N-(deoxy-
guanosin-N2-yl)ABP (5%) (11,28). The deoxyadenosine
adduct was unusual in that it was substituted at C8,
whiletheN2-deoxyguanosineadductwasinterestingbe-
cause it contained a hydrazo linkage. When dogs were
administered ABP a similar ratio ofadducts (11,28) was
found with N-(deoxyguanosin-8-yl)-ABP being the ma-
jor product (76%), followed by N-(deoxyguanosin-N2-
yl)-ABP (15%), and then N-(deoxyadenosin-8-yl)-ABP
(9%). Binding to urothelial DNA increased between 1
and 2 days, and appeared to remain constant for an
additional 5 days. ABP gave the most extensive binding
of the arylamine carcinogens examined, which corre-
lated with it being the strongest carcinogen. However,
essentiallythesamelevelofbinding, adductdistribution
and persistence were found in the liver, which is not a
target for ABP.
4-Acetylamino-4'-fluorobiphenyl
Substitution of AABP with a 4'-fluoro group results
in a compound that induces renal as well as hepatic and
mammarygland tumors inrats (29-31). Kriekand Hen-
geveld (32) have examined the DNA adducts present in
both liver and kidney in rats administered asingle dose
of the arylhydroxamic acid, N-hydroxy-4-acetylamino-
4'-fluorobiphenyl (AAFBP). A similar level of binding
was found in both tissues with the majority (80%) ofthe
adducts being nonacetylated. The nonacetylated ad-
ducts were not characterized but were suggested to be
decomposition products of N-(deoxyguanosin-8-yl)-4-
amino-4'-fluorobiphenyl (AFBP) (Fig. 6). Two acety-
lated adducts were found in equal concentrations; one
was identified asN-(deoxyguanosin-8-yl)-AAFBP while
the other was proposed to be 3-(deoxyguanosin-N2-yl)-
AAFBP. At nontoxic doses (5 mg/kg), the nonacety-
lated adducts were lost from both tissues with a half-
life of 10 days; N-(deoxyguanosin-8-yl)-AAFBP was re-
moved much faster (t1,2 = 2 days), while 3-(deoxy-
guanosin-N2-yl)-AAFBP appeared to be a persistent le-
sion. When a 25 mg/kg dose was administered, there
was an initial fast rate of removal of all adducts in the
kidney which was attributed to a toxic response.
3,2'-Dimethyl-4-aminobiphenyl
3,2'-Dimethyl-4-aminobiphenyl (DMABP) is unique
among arylamines in that it is primarily a colon carcin-
ogen in rats (33-35). In a manner analogous to aryl-
amine bladder carcinogens, DMABP has beenproposed
(36) to be N-oxidized and N-glucuronidated in the liver
to yield N-hydroxy-DMABP-N-glucuronide, which is
transported in the bile to the intestine where it can be
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FIGURE 6. DNA
fluorobiphenyl.
adducts derived from 4-acetylamino-4'-
cleaved to release N-hydroxy-DMABP. Nussbaum et
al. (36) have provided support for this mechanism by
detecting N-hydroxy-DMABP-N-glucuronide as a bili-
ary metabolite of DMABP. Flammang et al. (37) have
shownthatN-hydroxy-DMABP willreact with DNAin
vitro and that the extent ofbinding is greatly increased
by AcCoA-dependent transacetylation that presumably
yields N-acetoxy-DMABP. Further evidence for N-hy-
droxy-DMABP as a proximate carcinogen has been ob-
tained by comparing hepatic and intestinal DNA adducts
following a single subcutaneous injection ofDMABP or
its hydroxamic acid, N-acetyl-N-hydroxy-DMABP (38).
In both tissues, two adducts were found: N-(deoxy-
guanosin-8-yl)-DMABP (80%) and 5-(deoxyguanosin-N2-
yl)-DMABP (20%) (Fig. 7). N-Acetylated adducts were
not detected, and the extent of binding as well as the
adduct profile obtained from N-acetyl-N-hydroxy-
DMABP was nearly the same as that found with
DMABP. These data suggest that N-hydroxy-DMABP
serves as a common intermediate for both compounds.
The initial binding of DMABP to hepatic DNA was
approximately twice that observed in intestinal DNA
and the adducts in the liver were more persistent with
only 30% being lost within 7 days as compared to 70%
in the intestine. The greater persistence and higher
adduct levels found in the liver appeared to be incon-
sistent with the tissue specificity ofDMABP. However,
when the rates of de novo DNA synthesis were meas-
ured, the rate in the intestine was at least 20 times that
found in the liver. It seems, therefore, that although
total binding is lower in the intestinal DNA, the highly
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FIGURE 7. DNA adducts derived from 3,2'-dimethyl-4-
aminobiphenyl.
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proliferative nature of this tissue increases the proba-
bility that these adducts will serve as initiating lesions.
2-Acetylaminofluorene
2-Acetylaminofluorene (AAF), which is undoubtedly
the most extensively studied of the arylamine carcino-
gens, induces tumors in a number of species and at a
number ofsites including liver, mammary gland, intes-
tine, and urinary bladder (39-41). In rat liver, both
acetylated and nonacetylated adducts are formed with
the latter products accounting for approximately 80%
ofthe totalbinding aftera single administration ofAAF
or N-hydroxy-AAF (42-44). The major acetylated ad-
duct in rat liver, which has been identified as N-(deoxy-
guanosin-8-yl)-AAF (Fig. 8), contributes about 15% of
the total binding and has a half-life of 7 days in vivo
(43-45). In contrast, the minor acetylated adduct, 3-
(deoxyguanosin-N2-yl)-AAF, which accounts for 5% of
thebinding, is apersistentlesioninhepatic DNA(44,45).
The majority of adducts found in rat liver are non-
acetylated products that for many years resisted iden-
tification. Although they were suspected to be C8-deox-
yguanosine derivatives, these adducts tended to undergo
decomposition during DNA isolation and hydrolysis. It
is now known that this was due to a base-catalyzed
opening of the imidazole ring that yielded two pyrimi-
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dine adducts (46). When the isolation and hydrolysis
were performed under milder conditions, chromato-
graphicanalysis ofratliverDNAindicated the presence
of one major nonacetylated adduct, N-(deoxyguanosin-
8-yl)-2-aminofluorene (AF) (47,48) (Fig. 8). This has been
confirmed by both immunoassays (50) and 32P-postla-
beling (51) techniques. As was observed with 3-(deox-
yguanosin-N2-yl)-AAF, this nonacetylated adduct is
relatively persistent in rat liver DNA (47,49-52).
Recently Gupta and Dighe (24) have examined in
greater detail adduct formation and removal in rat liver
DNA after a single intraperitoneal injection of N-hy-
droxy-AAF. While their data generally agree with ear-
lier studies, there are a couple ofimportant exceptions.
First, due to the sensitivity of their 32P-postlabeling
method, they were able to detect many more adducts.
Two of these, which accounted for 50% of the initial
binding, were originally thought to be a new type of
adductbut have subsequently been found to result from
incompletehydrolysis ofthemodified DNA (Gupta, per-
sonal communication). Nevertheless, it is clear from
these results, as well as their earlier study (51), that a
greatervariety ofadducts than originally suspected can
be formed from AAF. Second, when adduct formation
was measured as early as 30 min aftertreatment, there
was a substantially greater proportion ofacetylated ad-
ducts than previously reported.
Inprinciple, anumberofmetabolic pathways can lead
to the adducts detected in rat liver. Through the use of
a sulfotransferase inhibitor, pentachlorophenol, Meer-
man et al. (48,53) have provided evidence that the pre-
dominant route to acetylated adducts is through the
formation ofN-sulfonyloxy-AAF. The situation regard-
ingthe nonacetylated adducts is less clear and evidence
has been presented supporting N, O-acyltransferase-
catalyzed formation ofN-acetoxy-AF (21,54,55), direct
reaction byN-hydroxy-AF (56), and AcCoA-dependent
formation ofN-acetoxy-AF(22).
Relatively few studies have been performed where
hepatic adducts have been examined after multiple or
chronic administration of AAF or N-hydroxy-AAF. In
one experiment, both male and female Sprague-Dawley
rats were administered up to four doses ofN-hydroxy-
AAF at biweekly intervals (49). N-(Deoxyguanosin-8-
yl)-AAF was detected in the hepatic DNA from male
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FIGURE 9. DNA adducts derived from benzidine.
23BELAND AND KADLUBAR
rats only and only on the day after dosing, whereas 3-
(deoxyguanosin-N2-yl)-AAF could be found both 1 and
14 days after treatment and increased in an additive
manneruponrepeated administration ofthecarcinogen.
N-(Deoxyguanosin-8-yl)-AF was the major adduct ob-
served in the liver DNA from males and also appeared
to increase in an additive manner. Only nonacetylated
adducts were detected in the hepatic DNA from fe-
males, which is consistent with the low sulfotransferase
levels in females of this strain (57). The total concen-
tration of adducts was higher in females and these ad-
ducts tended to persist. Since females are resistant to
N-hydroxy-AAF-induced hepatocarcinogenesis (58),
these results emphasize that adduct persistence alone
is not predictive of carcinogenesis.
In a series of experiments, Poirier et al. (50,59,60)
have used immunoassays to analyze adduct formation
and removal during dietary administration of AAF.
When rats were given either 0.02 or 0.04% AAF, the
concentration of adducts in the liver reached a plateau
ofabout 300 pmole/mg DNA afterapproximately 3 weeks
offeeding. Although acetylated adducts originallymade
a significant contribution to the total adduct concentra-
tion, by the time equilibrium was reached almost all of
the adductswerenonacetylated. Byusingacombination
ofradioactive and nonradioactive AAF (60), they dem-
onstrated that the capability of the liver to form and
remove adducts remained constant for at least 1 month
and that adduct removal did not depend upon continued
carcinogen ingestion. In addition, they found the re-
moval of adducts to be biphasic, which resulted in a
significant proportion of the adducts being persistent.
From these data a model was proposed in which there
weretwodistinctregionsinthegenome: onesusceptible
to fast repair, and another where repair occurred much
slower. Although a much greater number of adducts
were formed in the fast repair region, the model pre-
dicted that the persistent lesions resided exclusively in
the slow repair region.
The adducts formed from AAF or N-hydroxy-AAF
have also been examined in rat kidney and mammary
gland. After multiple doses ofN-hydroxy-AAF or after
dietary AAF, binding to kidney DNA was between 20
and 50 % ofthat found inhepatic DNA (49,50). The only
adduct detected was N-(deoxyguanosin-8-yl)AF and this
lesionpersisted foratleast 1 monthfollowingcarcinogen
administration. N-(Deoxyguanosin-8-yl)-AF was also the
only adduct found in rat mammary gland epithelium
after a single intraperitoneal dose of N-hydroxy-AAF
(61). In this experiment, the maximum adduct concen-
tration was found 4 hr after treatment and then de-
creased following first-order kinetics with a half-life of
14 days.
Amongthe aromatic amine carcinogens, AAF is unique
in that it induces both bladder and liver tumors in dogs
(41). In both tissues, N-(deoxyguanosin-8-yl)-AF was
the major adduct detected after a single dose of AAF
(11); it was the only adduct in epithelial DNA, whereas
other minor adducts were found in hepatic DNA. When
the adduct levels were compared at 2 and 7 days fol-
lowing administration, there was an 80% decrease in
both tissues which could be due to DNA repair or
cytotoxic responses. Since dogs readily deacetylate AAF
(26,27), the formation ofa nonacetylated adduct is con-
sistent with N-hydroxy-AF being the reactive inter-
mediate. However, it has recently been reported that
dog bladders contain high levels of PHS (18) that can
activateAFtoDNAbindingderivatives (16). Themajor
adduct formed in vitro from PHS-catalyzed cooxidation
appears to differ fromN-(deoxyguanosin-8-yl)-AF (62),
butitsidentityisnotknown. Whetherornotthis adduct
is formed in vivo also remains to be established.
When N-hydroxy-AAF was administered intraperi-
toneally to 12-day-old B6C3F1 mice, a high incidence of
hepatic tumors resulted and this could be decreased by
priortreatmentwiththesulfotransferase inhibitor, pen-
tachlorophenol (63). In addition, only a low tumor in-
cidence was found when N-hydroxy-AAF was
administered to a sulfotransferase-deficient strain. These
results suggest that N-sulfonyloxy-AAF should be the
ultimate carcinogenic metabolite; however, when the
hepatic adducts were examined, the major product de-
tected was the nonacetylated derivative N-(deoxy-
guanosin-8-yl)-AF, withtheacetylatedadductsaccount-
ing for only 5% ofthe binding. Since pentachlorophenol
decreased both the tumor yield and adduct formation,
it appears that in these mice N-hydroxy-AAF is deacet-
ylated to N-hydroxy-AF that is then converted to the
ultimate carcinogenN-sulfonyloxy-AF. Support forthis
interpretation was provided by the observation that N-
(deoxyguanosin-8-yl)-AF was formed in in vitro sulfo-
transferase assays conducted with mouse liver cytosol,
N-hydroxy-AF and deoxyguanosine (63). Interestingly,
when the model ultimate carcinogen N-acetoxy-AAF
was administered to mice through the orbital sinus, the
major adduct detected in lung (target) and liver (non-
target) DNA was N-(deoxyguanosin-8-yl)-AF, instead
of the acetylated adducts which would have been ob-
tained ifthis compound was reacted with DNA in vitro
(Drinkwater and Beland, unpublished observations). The
mechanism for this is not known but may involve N-
deacetylation ofN-acetoxy-AAF to N-acetoxy-AF.
Benzidine
Benzidine (BZ) is a urinary bladder carcinogen in
humans (64-66) and dogs (25), and a hepatocarcinogen
in rats, mice, and hamsters (66-69). Since BZ has two
amino functions, its metabolic activation pathways are
potentially more complicated than the monofunctional
aromatic amines. In order to elucidate these pathways,
BZ and its N-acetylated derivatives were administered
to rats and the binding to hepatic DNA was compared
(70-72). The relative order of binding was N-acetyl-
BZ> BZ >> N, N'-diacetyl-BZ, which indicated that
monoacetylationwaspartofthe activation sequence but
that the addition of a second acetyl group resulted in a
detoxified product. Based upon this information, N-hy-
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droxy-N'-acetyl-BZ, asuspected activated derivative of
N-acetyl-BZ was synthesized, reacted with DNA, and
the adduct profile was compared to that obtained in
vivo. Usingthis approach, the majorinvivo adduct was
identified as N-(deoxyguanosin-8-yl)-N'-acetyl-BZ (Fig.
9), a product derived either directly from N-hydroxy-
N'-acetyl-BZ orafterO-esterification ofthisN-hydroxy
arylamine. When the extent of binding was compared
at 1 and 7 days after a single intraperitoneal injection
of N-acetyl-BZ, the concentration of this adduct was
found to decrease by 60%. Similar kinetics of removal
had been observed earlier by Martin and Ekers (73),
who found a 40% decrease in hepatic DNA binding be-
tween 1 and 2 days and then a constant binding level
for at least an additional 4 weeks. Subsequently, by
using N, N'-diacetylbenzidine with higher specific ac-
tivity, a second adduct, N-(deoxyguanosin-8-yl)-N,N'-
diacetyl-BZ, was detected in rat liver in vivo at ap-
proximately 15% of the level of the major adduct (72).
The adducts formed from BZ or its N-acetylated de-
rivativeshave alsobeenexaminedinotherexperimental
animals. In mice, a single adduct, N-(deoxyguanosin-8-
yl)-N'-acetyl-BZ, was found following administration of
BZ in the drinking water for 1 week (70). The highest
binding was observed immediately after treatment; it
decreased by about 50% in 1 day, and then remained at
a constant level for at least an additional week. The
extent ofbinding and kinetics ofremoval ofthis adduct
were the same in male and female mice, although fe-
males were much more susceptible to hepatic tumor
inductionbyBZ (69). Inhamsters (72), the same adduct,
N-(deoxyguanosin-8-yl)-N'-acetyl-BZ wasfound inliver
DNAfollowing asingle IPinjectionofN-acetyl-BZ. The
concentration of this adduct was 50% of that observed
in rats, but the kinetics of removal appeared similar
with approximately a 50% reduction occurring between
1 and 7 days after treatment.
BZ-derived adducts have also been examined in dogs
(11). As noted earlier, BZ is abladder carcinogen inthis
species (25) which may be due to their low N-acet-
ylase activity (26,27). When a single dose of BZ was
given to dogs, a low level ofbinding could be detected
inurothelial DNA (11). Although amuchhigherbinding
was observed when N-acetyl-BZ was given, < 10% ap-
peared to be N-(deoxyguanosin--yl)-N'-acetyl-BZ. Both
BZ and N-acetyl-BZ gave very high levels of hepatic
DNA binding but < 1% could be released upon a stan-
dard enzymatic hydrolysis as opposed to the 70 to 90%
with other arylamine carcinogens. The identity ofthese
products has not yet been determined.
Since high levels of PHS have been detected in dog
bladder (18), cooxidation of BZ by this enzyme could
result in some of the binding observed in vivo. In ad-
dition, the liver has a variety ofperoxidases that could
catalyze the hepatic oxidation of BZ to DNA-binding
derivatives. Peroxidase-mediated cooxidation of BZ in
vitro has been demonstrated (18,74), and a major DNA
adduct arising from this oxidation has recently been
identified as N-(deoxyguanosin-8-yl)-BZ (Fig. 9) (75).
Whether or not this adduct accounts for some of the
unidentified adducts in the bladder and liver remains to
be determined. The presence oftwo amine functions in
BZ also offers the possibility that dyelike crosslinked
products (i.e., DNA-DNA or DNA-protein) may be
formed during its oxidation. This would presumably be
a minor pathway in rodent species that readily N-acet-
ylate BZ.
N,AN-Dimethyl-4-aminoazobenzene,
N-Methyl-4-aminoazobenzene and
4-Aminoazobenzene
N,N-Dimethyl-4-aminoazobenzene (DAB)wasamong
the first carcinogens found that induced tumors at a
location removed from the site ofapplication (76). This
observation, plus DAB's high molar extinction coeffi-
cient at visible wavelengths (which facilitated its study
inthedaysprecedingradiolabeled compounds), resulted
in a number ofinvestigations being conducted with this
aminoazo dye (2). The first step in the metabolic acti-
vation of DAB is a cytochrome P-450-catalyzed oxida-
tive N-demethylation to N-methyl-4-aminoazobenzene
(MAB) (2,77). Since a second N-demethylation, which
yields 4-aminoazobenzene (AB), generally results in a
decrease in carcinogenicity, most studies have concen-
trated on MAB, which is further activated by FMO-
catalyzed N-oxidation to N-hydroxy-MAB and then is
converted to an ultimate carcinogen through PAPS-de-
pendent formation ofN-sulfonyloxy-MAB.
A number of adducts have been characterized from
MAB in vivo. In rat liver, a target for MAB, two ad-
ducts were detected following the administration of a
single oral dose. The major adduct, N-(deoxyguanosin-
8-yl)-MAB (Fig. 10), which was first described by Lin
et al. (78), initially accounted for 70% ofthe bound ma-
terial but was rapidly removed and could not be de-
tected 7 days aftertreatment (77-79). The second adduct
wasidentifiedas3-(deoxyguanosin-N2-yl)-MAB andwas
found to be a persistent lesion whose concentration re-
mained constant foratleast2weeks (77,79). Whenmul-
tiple doses ofMAB were administered and the adducts
examined 8 hr after treatment, a third product was
detected and subsequently identified as 3-(deoxyaden-
osin-N6-yl)-MAB (80). Each ofthe adducts increased in
concentration with repeated administration with the rate
of increase being faster with 3-(deoxyguanosin-N2-yl)-
MAB and 3-(deoxyadenosin-N6-yl)-MAB. These kinet-
ics are consistent with the rapid repair of N-(deoxy-
guanosin-8-yl)-MAB in rat liver. More recently, the
adduct proffle has been determined after feeding MAB
to Sprague-Dawley rats for 1,3, or 5 weeks (81). Im-
mediately after treatment, the binding to hepatic DNA
was 3- to 10-fold higherthanthatfoundinthenontarget
tissues, kidney and spleen. Within 3 days the hepatic
adduct concentration had decreased by 50%; and when
the adduct profiles were determined, the only adduct
that appeared to persist was 3-(deoxyguanosin-N2-yl)-
MAB.
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FIGURE 10. DNA adducts derived from N,N-dimethyl-4-aminoazobenzene, N-methyl-4-aminoazobenzene and 4-aminoazobenzene.
Tarpley et al. (82) have examined the hepatic DNA
adducts in 12-day-old mice administered a single IP in-
jection of either MAB or DAB. At least 12 products
were detected due, in part, to a cis-trans isomerism
about the azo linkage. As had been observed with rats,
the major adduct was N-(deoxyguanosin-8-yl)-MAB,
which was rapidly removed from the DNA with 70%
being lost within 10 days after administration. Signifi-
cant quantities of 3-(deoxyguanosin-N2-yl)-MAB were
also found, and in a manner similar to what was found
in rat liver, this adduct was relatively persistent with
only 30% being removed within 10 days.
Although AB is not carcinogenic to adult rats, recent
studies indicate that it is nearly as hepatocarcinogenic
as MAB and DAB in preweanling mice (83,84). When
the hepatic DNA adducts were examined 1 day follow-
ing a single IP injection of AB, only one adduct, N-
(deoxyguanosin-8-yl)-AB, was detected (84). The same
adduct was found in DAB-treated mice, although it was
only about 25% of the level observed in mice adminis-
teredAB. Inaddition, twootheradductswereidentified
in the DAB-treated animals: N-(deoxyguanosin-8-yl)-
MAB and 3-(deoxyguanosin-N2-yl)-MAB. Inlight ofthe
observation that N-hydroxy-AF is activated by for-
mation of a sulfate ester in mouse liver and that this
tissue contains very low levels of N,O-acyltransferase
and acetylCoA-dependent O-acetylase, itappearslikely
that the major pathway leading to hepatic AB adducts
is through the formation ofN-sulfonyloxy-AB.
2-Acetylaminophenanthrene
2-Acetylaminophenanthrene(AAP) is another aro-
matic amide which gives substantial levels of hepatic
DNA binding (24,85,86) although it is not hepatocarcin-
ogenic, either with (86,87) or without (88) promotion.
In order to determine the reason for this, Scribner and
Koponen (85) compared the hepatic DNA adducts formed
from AAP to those obtained from AAF following a sin-
gle IP injection to male Fischer rats. Both compounds
gave approximately equal levels of binding and a sub-
stantial amount of persistent adducts; however, only
nonacetylated adducts, of which two were major and
twowere minor, were detected from AAP. Equal levels
ofbindingwere also detected when rats were fed either
ofthe aromatic amides (86). More recently, Gupta and
Dighe have reexamined the kinetics of formation and
removal ofAAP adducts following a single administra-
tion ofN-hydroxy-AAP (24). At 4 hr, the hepatic DNA
binding of N-hydroxy-AAP was much lower (approxi-
mately 10%) than that observed with N-hydroxy-AAF.
However, by 24 hr the binding was nearly equal, and,
10 days after carcinogen administration, the binding
detected from N-hydroxy-AAP was substantially higher
than that found with N-hydroxy-AAF. Examination of
the adduct proffle revealed two major and at least eight
minor adducts all ofwhich could be formed by reacting
N-hydroxy-2-aminophenanthrene (AP) with calf thy-
mus DNA. Thus, in accord with the earlier results of
Scribner and Koponen (85), all ofthe adducts appeared
to be nonacetylated. Further insight into the identity
ofthe adducts was obtained by reactingN-hydroxy-AP
with synthetic deoxynucleoside polymers which indi-
cated that the two major adducts were derived from
substitution of deoxyguanosine. Preliminary spectro-
scopic data suggest that one of these products is N-
(deoxyguanosin-8-yl)-AP (89) (Fig. 11), similar to a
guanosine product originally reported by Scribner et al.
(86).
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FIGURE 11. DNAadduct derived from2-acetylaminophenanthrene.
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Conclusions
Over the last decade, the identification of aromatic
amine-DNA adducts has provided new insights into the
mechanisms of metabolic activation, mutagenicity and
carcinogenicity. In general, the major sites of carcino-
gen modification in DNA have been C8 and N2 ofguan-
ine, with substitution at O6 ofguanine, and N6 and C8
ofadenine occurringto alesser extent. Dependingupon
themetabolic activationpathwayinvolved, thearomatic
amino groups of these adducts have been found to be
acetylated, nonacetylated or methylated. In fact, the
identity ofthese adducts, along with the overall adduct
profiles observed invivo, has provided strong evidence
for the role of specific metabolic conjugation reactions
that have been demonstrated in vitro.
Although target-tissue specificity of aromatic amine
carcinogens has correlated with the levels ofDNAmod-
ification and with the relative persistence of many of
these adducts, several exceptions have been noted in
this review. Thus, it is clear that adduct formation per
se is not sufficient for tumor initiation (fixation of a
heritable lesionthatcanleadtoneoplasia) andthatother
processes, such as error-prone repair and cellular rep-
lication, play an essential role. In addition, the relative
biologicalpotencyofaromaticamine-DNAadductsmay
differ appreciably from one another as evidenced by the
differing mutation efficiencies in Salmonella typhimu-
rium TA1538 and TA1535 (11), and in Chinese hamster
ovarycells (90). Furthermore, mutationalhotspots have
beenfoundinaromatic amine-modified DNA (91), which
indicatesthatthebiologicalactivity ofadductsisfurther
influenced by specific DNA sequences.
Analysis of carcinogen-induced changes in DNA se-
quence (91-93)hasoftenrevealedbasedeletions(frame-
shifts) which is consistent with invitro studies in which
the replication ofaromatic amine-modified DNA has re-
sultedinchaintermination (94,95). Inaddition, aromatic
amine substitution has also led to transversion muta-
tions (93). These aromatic amine-induced mutations are
thought to arise from conformational changes in DNA,
including conversion ofthe modified base from an anti
to syn conformation (11,91,94,96). This, in turn, results
in alterations in DNA conformation (B to Z; B/Z junc-
tions; altered B-form) which has been suggested to lead
to base deletions and specific mispairings (94,97-100).
Forexample, C8andN2-substituted guanineshavebeen
predicted to result in G to T or G to C transversions
(93,99), 06-modified guanines in G to A transitions (8),
and N6- and C8-substituted adenines in A to T or A to
C transversions (99). Therefore, it may not be coinci-
dental that activation of cellular transforming genes of
the ras family (c-rasH, c-rasK, and c-rasN), which has
been implicated in bladder, colon, liver, mammary, lung,
nervous system and embryonaltumors, canbe achieved
byGtoTtransversions (101-103) and GtoAtransitions
(104,105) at coding position 12 and A to T transversions
(106) at coding position 61 ofthe first exon. Additional
studies of the consequences of aromatic amine-DNA
adducts should be pursued and may provide important
data on the molecular biology of cancer.
We thank Susan S. Beland for help in preparing this review.
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